250 related articles for article (PubMed ID: 25958744)
1. Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk?
Rozenberg S; Antoine C; Vandromme J; Fastrez M
Climacteric; 2015; 18(4):448-52. PubMed ID: 25958744
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormonal therapy in surgically menopausal women with underlying endometriosis.
Tanmahasamut P; Rattanachaiyanont M; Techatraisak K; Indhavivadhana S; Wongwananuruk T; Chantrapanichkul P
Climacteric; 2022 Aug; 25(4):388-394. PubMed ID: 34783284
[TBL] [Abstract][Full Text] [Related]
3. Menopausal hormone therapy and breast cancer risk.
Rozenberg S; Di Pietrantonio V; Vandromme J; Gilles C
Best Pract Res Clin Endocrinol Metab; 2021 Dec; 35(6):101577. PubMed ID: 34535397
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
5. EMAS position statement: Managing the menopause in women with a past history of endometriosis.
Moen MH; Rees M; Brincat M; Erel T; Gambacciani M; Lambrinoudaki I; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rozenberg S;
Maturitas; 2010 Sep; 67(1):94-7. PubMed ID: 20627430
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
Petrick JL; Joslin CE; Johnson CE; Camacho TF; Peres LC; Bandera EV; Barnard ME; Beeghly A; Bethea TN; Dempsey LF; Guertin K; Harris HR; Moorman PG; Myers ER; Ochs-Balcom HM; Rosenow W; Setiawan VW; Wu AH; Schildkraut JM; Rosenberg L
Br J Cancer; 2023 Dec; 129(12):1956-1967. PubMed ID: 37865688
[TBL] [Abstract][Full Text] [Related]
7. Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy.
Jordan SJ; Wilson LF; Nagle CM; Green AC; Olsen CM; Bain CJ; Pandeya N; Whiteman DC; Webb PM
Aust N Z J Public Health; 2015 Oct; 39(5):434-40. PubMed ID: 26437728
[TBL] [Abstract][Full Text] [Related]
8. Menopausal hormone therapy in women with benign gynaecological conditions and cancer.
Brennan A; Rees M
Best Pract Res Clin Endocrinol Metab; 2021 Dec; 35(6):101575. PubMed ID: 34686433
[TBL] [Abstract][Full Text] [Related]
9. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.
Rees M; Angioli R; Coleman RL; Glasspool R; Plotti F; Simoncini T; Terranova C
Maturitas; 2020 Apr; 134():56-61. PubMed ID: 32059825
[TBL] [Abstract][Full Text] [Related]
10. [Drugs and cancer risk: the example of THM].
Fournier A; Hill C
Rev Prat; 2013 Oct; 63(8):1117-21. PubMed ID: 24298831
[TBL] [Abstract][Full Text] [Related]
11. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
12. Menopausal hormone therapy (MHT): refining our understanding of MHT research, optimally applying results, and considering the future of MHT.
Anagnostis EA
J Pharm Pract; 2012 Jun; 25(3):324-30. PubMed ID: 22550160
[TBL] [Abstract][Full Text] [Related]
13. Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Anagnostis P; Paschou SA; Katsiki N; Krikidis D; Lambrinoudaki I; Goulis DG
Curr Vasc Pharmacol; 2019; 17(6):564-572. PubMed ID: 29984659
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
15. Hysterectomy and risk of epithelial ovarian cancer by histologic type, endometriosis, and menopausal hormone therapy.
Ring LL; Baandrup L; Zheng G; Gottschau M; Dehlendorff C; Mellemkjær L; Kjaer SK
Cancer Epidemiol; 2023 Jun; 84():102359. PubMed ID: 37054550
[TBL] [Abstract][Full Text] [Related]
16. [Menopausal hormonal therapy and cancer risks].
Lasserre A; Fournier A
Gynecol Obstet Fertil; 2016; 44(7-8):424-7. PubMed ID: 27451070
[TBL] [Abstract][Full Text] [Related]
17. Endometriosis after menopause: physiopathology and management of an uncommon condition.
Streuli I; Gaitzsch H; Wenger JM; Petignat P
Climacteric; 2017 Apr; 20(2):138-143. PubMed ID: 28286987
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
19. [Borderline Ovarian Tumours: CNGOFS Guidelines for Clinical Practice - Hormonal Contraception and MHT/HRT after Borderline Ovarian Tumour].
Rousset-Jablonski C; Pautier P; Chopin N
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):337-340. PubMed ID: 32004788
[TBL] [Abstract][Full Text] [Related]
20. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency.
Armeni E; Paschou SA; Goulis DG; Lambrinoudaki I
Best Pract Res Clin Endocrinol Metab; 2021 Dec; 35(6):101561. PubMed ID: 34274232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
